Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 110,000 |
5 mg | 在庫あり | ¥ 248,000 |
25 mg | 在庫あり | ¥ 395,000 |
50 mg | 在庫あり | ¥ 500,500 |
100 mg | 在庫あり | ¥ 638,000 |
説明 | KCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI). |
分子量 | 334.33 |
分子式 | C19H14N2O4 |
CAS No. | 1952276-71-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KCL-286 1952276-71-9 Metabolism Retinoid Receptor Inhibitor inhibitor inhibit